Compared to patients without T2D, a larger proportion of those with T2D received kidney-protective treatment (SGLT-2 inhibitors, 24% versus 4%; RAS inhibitors, 63% versus 47%). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.